Noxxon Pharma N.V. (EuroNext Growth Paris: ALNOX)

https://www.noxxon.com

NOXXON’s oncology-focused pipeline acts on the tumor microenvironment (TME) and the cancer immunity cycle by breaking the tumor protection barrier and blocking tumor repair. By neutralizing chemokines in the TME, NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. NOXXON’s lead program NOX-A12 has delivered final top-line data from a Keytruda® combination trial in metastatic colorectal and pancreatic cancer patients published at the ESMO conference in September 2020 and in July 2021 the company announced its Phase 2 study, OPTIMUS, to further evaluate safety and efficacy of NOX-A12 in combination with Merck’s Keytruda® and two different chemotherapy regimens as second-line therapy in patients with metastatic pancreatic cancer. NOXXON is also studying NOX-A12 in brain cancer in combination with radiotherapy which has been granted orphan drug status in the US and EU for the treatment of certain brain cancers. GLORIA, a trial of NOX-A12 in combination with radiotherapy in newly diagnosed brain cancer patients who will not benefit clinically from standard chemotherapy has delivered interim data from the first two cohorts showing consistent tumor reductions and objective tumor responses. The company’s second clinical-stage asset NOX-E36 is a Phase 2 TME asset targeting the innate immune system. NOXXON plans to test NOX-E36 in patients with solid tumors. *

	Group	TME Pharma (Group)
	Today	TME Pharma N.V. (EuroNext Growth Paris: ALTME)
	Predecessor	Noxxon Pharma AG
	Successor	TME Pharma N.V. (EuroNext Growth Paris: ALTME)
	Industry	olaptesed pegol (NOX-A12)
	Industry 2	Spiegelmer® technology
	Person	Mangasarian, Aram (Noxxon 201005 CBO before Novexel since 200511 VP BusDev before ExonHit VP BusDev)

	Region	Amsterdam
	Country	Netherlands
	City	n. a. Amsterdam
		Address record changed: 2024-01-05

Basic data	Employees	n. a.
	Currency	EUR
	Profit	-5,390,000 (2017-12-31)
	Cash	622,000 (2017-12-31)

		* Document for »About Section«: Noxxon Pharma N.V.. (10/27/21). "Press Release: Experienced Financial Executive, Bryan Jennings, Joins Noxxon as CFO". Berlin.

		Record changed: 2024-02-12

Picture Kenes Exhibitions Biomed Israel 2024 Tel Aviv 650x200px

More documents for TME Pharma (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)